ClinicalTrials.gg
Active, not recruitingNCT07122752Updated Oct 8, 2026

Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy

An observational study in Traumatic Brain Injury, Acquired Brain Injury and Brain Tumor, sponsored by Tan Tock Seng Hospital. Active, not recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Tan Tock Seng Hospital · Observational

How we know

Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
32
Ages
21 Years and older
Sex
All
01

Study summary

This study will compare the outcomes of a current clinical implementation of PEACO designed for one-handed donning and doffing with carer-monitoring with a previous prototype (HPPD) requiring carer-donning and doffing with therapist monitoring.

Read the detailed description

The study aims to:

  1. Evaluate the feasibility, safety and clinical outcomes of a 3D-printed externally applied cranial orthosis (PEACO) in a clinical setting (unmonitored protocol)
  2. Comparison of device A - 2021 Head Protection Prototype Device (HPPD) (DSRB 2019/00155)-monitored protocol with device B (PEACO).
02

Conditions studied

  • Traumatic Brain Injury
  • Acquired Brain Injury
  • Brain Tumor
  • Stroke

Keywords

  • Cranial Orthosis
  • 3D Printing
  • Decompression Craniectomy
  • Retrospective Study
  • Head Protection Device
  • Monitored Protocol
  • Unmonitored Protocol
03

In context

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's enrollment of 32 is below the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Tan Tock Seng Hospital is the lead sponsor of 108 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

NA as no patient is recruited for this study as the outcomes involve retrospective data as part of a clinical service audit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral decompressive craniectomy (DC)
  • Acute Stroke or traumatic brain injury
  • >30 days post DC
  • Healed surgical wounds, non-bulging flaps
  • Presence of caregiver supervision

Exclusion criteria

Exclusion Criteria:

  • Vegetative or minimally responsive state
  • Uncontrolled medical illnesses, e.g. sepsis, delirium, active
  • \< 6 months
  • Unhealed or infected post-DC neurosurgical wounds
  • Known allergy to products
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
32 participants (actual)
Patient registry
No

Groups and cohorts

  • Version 1 Head protection Device 2021

    Version 2 Head protection device 2025

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (safety and tolerability)

    The therapist will assess patient in terms of pain, redness, skin imprints and pruritus' on patient's skin after wearing the cranial cap. This is to allow the understanding of the incidence of the treatment-emergent adverse events (safety and tolerability).

    Time frame: 30 minutes post fitting (version 1 and 2)

  2. Patient Reported Outcome Measures (PROMS) PROMs (compliance)

    The patient will be sent a questionnaire. The question relating to compliance is "Approximately, how many hours of wear per day including rest breaks?" This will allow team to assess feasibility, safety and clinical outcomes.

    Time frame: 2023-2025

  3. Patient Reported Outcome Measures (PROMS) PROMs (wearing time)

    The patient will be sent a questionnaire. The question relating to wearing time is "Approximately, how many hours of wear per day including rest breaks?" This will allow team to assess feasibility, safety and clinical outcomes.

    Time frame: 2023-2025

  4. Patient Reported Outcome Measures (PROMS) PROMs (adverse events)

    The patient will be sent a questionnaire. The question relating to adverse event is "Did you experience any of the following after two hours of wear? This will allow team to assess feasibility, safety and clinical outcomes.

    Time frame: 2023-2025

  5. Patient Reported Outcome Measures (PROMS) PROMs (cosmesis rating)

    The patient will be sent a questionnaire. The question relating to cosmesis rating is "Please rate the appearance of your cranial cap". This will allow team to assess feasibility, safety and clinical outcomes.

    Time frame: 2023-2025

07

Study locations

1 site
08

References and documents

Publications

  • Chua KSG, Krishnan RR, Yen JM, Plunkett TK, Soh YM, Lim CJ, Chia CM, Looi JC, Ng SG, Rao J. 3D-printed external cranial protection following decompressive craniectomy after brain injury: A pilot feasibility cohort study. PLoS One. 2021 Oct 28;16(10):e0258296. doi: 10.1371/journal.pone.0258296. eCollection 2021. PubMed 34710123 ↗
  • Fernandez LL, Rodriguez D, Griswold DP, Khun I, Aristizabal S, Aristizabal JH, Richards G, Pavek A, Jayaraman S. Innovative External Cranial Devices for Protecting a Craniectomy Site: A Scoping Review on Noninvasive Approaches for Patients Awaiting Cranioplasty. Neurosurgery. 2025 Apr 1;96(4):713-724. doi: 10.1227/neu.0000000000003157. Epub 2024 Sep 9. PubMed 39248525 ↗
  • Ma S, Li C, Gu Y, Chen Y, Li X, Wang Q, Xu H. Application of a 3D printed wig protection device after decompressive craniectomy. Sci Rep. 2025 Mar 19;15(1):9545. doi: 10.1038/s41598-025-94246-0. PubMed 40108252 ↗

Individual participant data

Plan to share: No — no new IP generated

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 14, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Aug 29, 2027was Aug 2026
CompletionEst.
Aug 29, 2027was Aug 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 29, 2026→Aug 29, 2027
Oct 8, 2026
Study completion
Aug 29, 2026→Aug 29, 2027
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Aug 29, 2026→Aug 29, 2027
    Study completion Aug 29, 2026→Aug 29, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07122752
Responsible party
Chua Sui Geok, Karen (Senior Consultant Dr (MD), Tan Tock Seng Hospital) — Principal investigator
First posted
Aug 14, 2025
Start date
Jul 29, 2025
Primary completion
Aug 29, 2027 (estimated)
Completion
Aug 29, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Dr Karen Chua, MBBS
principal investigator · Tan Tock Seng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion